Arca
Skip to content
Tools
Tools

F10, F9: Coagulation factor IX and X

Selectivity group in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on F10, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1

Approved1

  • Emicizumab

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        EmicizumabBoxed warningApprovedRocheAntibodyOtherCoagulation factor IX and X other25

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving EmicizumabEmicizumab—Not yet recruitingUniversity Hospital, CaenNov 18, 2026
        Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)Emicizumab—RecruitingHospices Civils de LyonJul 23, 2026
        TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII TherapiesEmicizumab—RecruitingUniversity of Texas Southwestern Medical CenterJul 9, 2026
        A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)Emicizumab—RecruitingArkansas Children's Hospital Research InstituteMay 12, 2026
        Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia AEmicizumabPhase 2 / Phase 3Active, not recruitingChulalongkorn UniversityFeb 27, 2026
        Incidence of Ultrasonographically Detected Articular Damage in Initially Healthy Joints of Patients With Hemophilia A Receiving Prophylactic Treatment With EmicizumabEmicizumab—Not yet recruitingInvestigación en Hemofilia y FisioterapiaFeb 19, 2026
        A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia AEmicizumabPhase 3RecruitingHoffmann-La RocheFeb 18, 2026
        Effects of Emicizumab Treatment in Patients With Hemophilia AEmicizumab—Not yet recruitingHasan Kalyoncu UniversitySep 24, 2025

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2111424, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.